NCT00509548 - Open-Label, Pilot Study of TG100801 in Patients With Choroidal Neovascularization Due to AMD | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

March 31, 2008

Study Completion Date

March 31, 2008

Conditions

Macular DegenerationChoroidal Neovascularization

Interventions

DRUG

TG100801

Eye drop, twice a day, 30 days.

Trial Locations (8)

Vitreous-Retina-Macula Consultants of New York, New York

Center for Retina and Macular Disease, Winter Haven

Cleveland Clinic, Cleveland

Black Hills Regional Eye Institute, Rapid City

Vitreoretinal Consultants, Houston

Retina Centers, PC, Tucson

Retina-Vitreous Associates Medical Group, Beverly Hills

Ophthalmic Consultants of Boston, Boston